[go: up one dir, main page]

FR2882931B1 - Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique - Google Patents

Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Info

Publication number
FR2882931B1
FR2882931B1 FR0502508A FR0502508A FR2882931B1 FR 2882931 B1 FR2882931 B1 FR 2882931B1 FR 0502508 A FR0502508 A FR 0502508A FR 0502508 A FR0502508 A FR 0502508A FR 2882931 B1 FR2882931 B1 FR 2882931B1
Authority
FR
France
Prior art keywords
cannabinoidess
receptors
association
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0502508A
Other languages
English (en)
Other versions
FR2882931A1 (fr
Inventor
Michele Arnone
Trillou Christine Ravinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0502508A priority Critical patent/FR2882931B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to RU2007138042/15A priority patent/RU2007138042A/ru
Priority to JP2008501356A priority patent/JP2008533110A/ja
Priority to AU2006224446A priority patent/AU2006224446A1/en
Priority to CA002600028A priority patent/CA2600028A1/fr
Priority to EP06726063A priority patent/EP1863489A1/fr
Priority to PCT/FR2006/000532 priority patent/WO2006097605A1/fr
Priority to KR1020077023434A priority patent/KR20070112266A/ko
Priority to MX2007011357A priority patent/MX2007011357A/es
Priority to BRPI0608438-9A priority patent/BRPI0608438A2/pt
Priority to CNA2006800081089A priority patent/CN101137373A/zh
Publication of FR2882931A1 publication Critical patent/FR2882931A1/fr
Application granted granted Critical
Publication of FR2882931B1 publication Critical patent/FR2882931B1/fr
Priority to IL185789A priority patent/IL185789A0/en
Priority to US11/854,032 priority patent/US20080015186A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0502508A 2005-03-14 2005-03-14 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique Expired - Fee Related FR2882931B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0502508A FR2882931B1 (fr) 2005-03-14 2005-03-14 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
CNA2006800081089A CN101137373A (zh) 2005-03-14 2006-03-10 含有大麻素受体拮抗化合物与防治精神病剂组合的药物组合物
AU2006224446A AU2006224446A1 (en) 2005-03-14 2006-03-10 Pharmaceutical compositions containing a combination of a cannabinoid receptor antagonist compound and an antipsychotic agent
CA002600028A CA2600028A1 (fr) 2005-03-14 2006-03-10 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoides et un agent antipsychotique
EP06726063A EP1863489A1 (fr) 2005-03-14 2006-03-10 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoides et un agent antipsychotique
PCT/FR2006/000532 WO2006097605A1 (fr) 2005-03-14 2006-03-10 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoides et un agent antipsychotique
RU2007138042/15A RU2007138042A (ru) 2005-03-14 2006-03-10 Фармацевтические композиции, содержащие в сочетании соединение-антагонист рецепторов каннабиноидов и нейролептическое средство
MX2007011357A MX2007011357A (es) 2005-03-14 2006-03-10 Composiciones farmaceuticas que contienen en asociacion un compuesto antagonista de los receptores de cannabinoides y un agente antipsicotico.
BRPI0608438-9A BRPI0608438A2 (pt) 2005-03-14 2006-03-10 composições farmacêuticas contendo em associação um composto antagonista dos receptores aos canabinóides e um agente antipsicótico
JP2008501356A JP2008533110A (ja) 2005-03-14 2006-03-10 カンナビノイド受容体アンタゴニスト化合物および抗精神病薬剤の組合せを含有する医薬組成物
KR1020077023434A KR20070112266A (ko) 2005-03-14 2006-03-10 칸나비노이드 수용체 길항제 화합물과 항정신병제의조합물을 함유하는 제약 조성물
IL185789A IL185789A0 (en) 2005-03-14 2007-09-06 Pharmaceutical compositions containing a combination of a cannabinoid receptor antagonist compound and an antipsychotic agent
US11/854,032 US20080015186A1 (en) 2005-03-14 2007-09-12 Pharmaceutical compositions containing in combination a cannabinoid receptor antagonist and an antipsychotic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502508A FR2882931B1 (fr) 2005-03-14 2005-03-14 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Publications (2)

Publication Number Publication Date
FR2882931A1 FR2882931A1 (fr) 2006-09-15
FR2882931B1 true FR2882931B1 (fr) 2007-05-18

Family

ID=34955355

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0502508A Expired - Fee Related FR2882931B1 (fr) 2005-03-14 2005-03-14 Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Country Status (13)

Country Link
US (1) US20080015186A1 (fr)
EP (1) EP1863489A1 (fr)
JP (1) JP2008533110A (fr)
KR (1) KR20070112266A (fr)
CN (1) CN101137373A (fr)
AU (1) AU2006224446A1 (fr)
BR (1) BRPI0608438A2 (fr)
CA (1) CA2600028A1 (fr)
FR (1) FR2882931B1 (fr)
IL (1) IL185789A0 (fr)
MX (1) MX2007011357A (fr)
RU (1) RU2007138042A (fr)
WO (1) WO2006097605A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000273A (es) * 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
ES2330071B1 (es) * 2007-01-15 2010-07-05 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.
EP1946777A1 (fr) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Composés de pyrazoline substituée pour éviter la prise de poids
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8566459B2 (en) 2009-05-29 2013-10-22 Red Hat, Inc. Systems and methods for integrated console management interface

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора

Also Published As

Publication number Publication date
MX2007011357A (es) 2007-11-12
EP1863489A1 (fr) 2007-12-12
IL185789A0 (en) 2008-02-09
CA2600028A1 (fr) 2006-09-21
RU2007138042A (ru) 2009-04-20
WO2006097605A1 (fr) 2006-09-21
CN101137373A (zh) 2008-03-05
JP2008533110A (ja) 2008-08-21
US20080015186A1 (en) 2008-01-17
AU2006224446A1 (en) 2006-09-21
KR20070112266A (ko) 2007-11-22
FR2882931A1 (fr) 2006-09-15
BRPI0608438A2 (pt) 2009-12-29

Similar Documents

Publication Publication Date Title
CY2019010I1 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
CY2021003I2 (el) Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεα αγγειοτενσινης και ενος αναστολεα νερ
EP1962827A4 (fr) Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la métformine
FR14C0020I1 (fr) Compositions pharmaceutiques contenant du fentanyl pour application nasale
ATE422150T1 (de) Mischung aus anthranilamid-invertebrat-pest- bekämpfungsmittel
CY2017027I1 (el) Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
CY2015060I1 (el) Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
EP2046736A4 (fr) Composés arylsulfanylés et compositions pour administrer des agents actifs
ATE502634T1 (de) N-methylaminomethyl-isoindol-verbindungen und diese enthaltende zusammensetzungen und diese verwendende verfahren
IL197275A0 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
EP2004175A4 (fr) Composés augmentant l'activité anticancéreuse, formulations les contenant et leurs méthodes d'utilisation
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
DE602007005655D1 (de) Negativ arbeitende strahlungsempfindliche zusammensetzung und bebilderbare materialien
PT1888081T (pt) Composições contendo pufa e seus métodos de utilização
FR2871057B1 (fr) Composition cosmetique contenant un ester et un agent filmogene
PL2027096T3 (pl) Podstawione aryloimidazolony oraz triazolony jako inhibitory receptorów wazopresyny
PL1861387T3 (pl) Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
EP1925319A4 (fr) Compositions pharmaceutiques contenant du sc(fv)2
EP2054961A4 (fr) Agents dissociants, formulations et procédés fournissant une solubilité augmentée des fluorures
PT1861387E (pt) Derivados de benzimidazol e composições farmacêuticas dos mesmos
IL176922A0 (en) Compositions and methods of use of a-type procyanidins
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
EP1808446A4 (fr) Antagoniste du recepteur il-18 et composition pharmaceutique contenant cet antagoniste

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20111130